Kymera Therapeutics

Company snapshot

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immun

• 12 active pipeline program(s) linked via ClinicalTrials.gov.
• 29 US patent(s) indexed to this assignee profile.
• 12 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Kymera Therapeutics. Not investment advice.

• Peer + 0 momentum

  Incyte

  TA overlap score 30.6

Recent activity

Latest pipeline, patent, and corporate events for Kymera Therapeutics.

1. Jun 8, 2026 Clinical update

   KT621-AS-202 — Phase 2

2. Jun 8, 2026 Clinical update

   KT621-AD-201 — Phase 2

3. Jun 5, 2026 Clinical update

   KT-474/Placebo — Phase 1

4. May 23, 2026 Clinical update

   KT-621 — Phase 2

5. May 23, 2026 Clinical update

   KT-621 — Phase 2

View all clinical trial activity →

• What is Kymera Therapeutics?

  Kymera Therapeutics is a biotech organization headquartered in Watertown, USA. It trades on NYSE under ticker KYMR. Primary therapeutic focus areas include Atopic Dermatitis, Moderate to Severe Atopic Dermatitis, Uncontrolled Moderate to Severe Eosinophilic Asthma, Myeloid Malign

• Is Kymera Therapeutics publicly traded?

  Yes. Kymera Therapeutics is listed with ticker KYMR on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Kymera Therapeutics develop or market?

  We link 6 drug profile(s) where Kymera Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/kymera-therapeutics#company-drugs.

• What are the latest developments for Kymera Therapeutics?

  In the last 12 months our linked public records show 12 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Kymera Therapeutics focus on?

  Kymera Therapeutics focuses on Atopic Dermatitis, Moderate to Severe Atopic Dermatitis, Uncontrolled Moderate to Severe Eosinophilic Asthma based on our analysis of their pipeline programs and drug development activities.